Literature DB >> 15042173

Adverse reactions associated with a Fuenzalida-Palacios rabies vaccine: a quasi-experimental study.

Rosuita Fratari Bonito1, Neide Mattar de Oliveira, Sérgio de Andrade Nishioka.   

Abstract

The Fuenzalida-Palacios rabies vaccine has been used in South America for rabies post-exposure prophylaxis. To determine the frequency of adverse reactions associated with this vaccine compared to a control group a quasi-experimental study was carried out in Uberlândia, Brazil, from May 1997 to April 1998. Victims of bites or other injuries by dogs or other mammals and who received or not post-exposure prophylaxis with Fuenzalida-Palacios rabies vaccine were compared as to the occurrence of a list of signs and symptoms. Out of 2,440 victims of bites and other injuries from dogs and other mammals 2,114 participated in the study; 1,004 of them provided follow-up information within 10 to 15 days. Headache and pain at the injection sites were the most commonly found symptoms (125/1,000). No neuroparalytic event was detected. Patients who were given Fuenzalida-Palacios rabies vaccine and those who were not had similar incidences of symptoms (risk ratios close to 1). Regarding the occurrence of adverse reactions, Fuenzalida-Palacios rabies vaccine is a valid alternative for rabies post-exposure prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042173     DOI: 10.1590/s0037-86822004000100002

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  2 in total

Review 1.  Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential.

Authors:  Shimao Zhu; Caiping Guo
Journal:  Viruses       Date:  2016-10-28       Impact factor: 5.048

2.  Risk Factors and Protective Immunity Against Rabies in Unvaccinated Butchers Working at Dog Slaughterhouses in Northern Vietnam.

Authors:  Anh Kieu Thi Nguyen; Anh Hoang Vu; Thu Tuyet Nguyen; Dong Vinh Nguyen; Giang Chau Ngo; Thai Quang Pham; Satoshi Inoue; Akira Nishizono
Journal:  Am J Trop Med Hyg       Date:  2021-08-02       Impact factor: 3.707

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.